The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma
Phase II trial of carboplatin and pemetrexed plus bevacizumab with maintenance bevacizumab as first-line treatment for elderly patients with advanced non-squamous non-small cell lung cancer.
 
Hiroaki Takeoka
No Relationships to Disclose
 
Kazuhiko Yamada
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Sharp & Dohme; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Lilly Japan (Inst)
 
Hidenobu Ishii
No Relationships to Disclose
 
Takaaki Tokito
No Relationships to Disclose
 
Koichi Azuma
No Relationships to Disclose
 
Yoshiko Naito
No Relationships to Disclose
 
Norikazu Matsuo
No Relationships to Disclose
 
Masao Ichiki
No Relationships to Disclose
 
Tomoaki Hoshino
No Relationships to Disclose